本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Lyell Immunopharma, Inc.

0.4612
-0.0088-1.87%
盘后0.46120.00000.00%16:10 EDT
成交量:49.04万
成交额:22.91万
市值:1.36亿
市盈率:-0.35
高:0.4850
开:0.4700
低:0.4549
收:0.4700
数据加载中...
2024/05/02

SEC问询函

Form CORRESP - Correspondence
2024/02/29

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/02/29

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/28

重要事件披露

Form 8-K - Current report
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/11/21

重要事件披露

Form 8-K - Current report
2023/11/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/08

重要事件披露

Form 8-K - Current report
2023/09/11

重要事件披露

Form 8-K - Current report
2023/08/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/08/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/08/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/08/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/08/08

重要事件披露

Form 8-K - Current report
2023/08/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/07/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/07/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/07/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/07/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities